Evolution of the Average Target: UCB

Evolution of the Average Target - UCB

Evolution of the Target Price: UCB

Evolution of the Target Price - UCB

Changes in Analyst Recommendations: UCB

04809dd6b11dff8ad435.s-T5mENgVW7NshVFK-YQ3oQmt5I6AHR74O6LLQucs74.9oCJ-i4ZIQuL8yYIdJZlredN-PRQSiNPr5amG2mtg_3ckZeuElYsIIj7IQ~d20f8b4e3104e03ff2dd1216972c0188
10-27 AlphaValue/Baader Europe Raises Estimates for UCB on Recent FY26 Outlook Upgrade MT
10-26 UCB: Undercommit and overdeliver – The UCB way Alphavalue
10-26 A Week of Reckoning for Wall Street Zonebourse
10-26 BofA Lifts UCB Price Objective, EPS Forecasts After 'Surprise' FY26 Guidance Upgrade MT
10-23 AlphaValue/Baader Europe Downgrades UCB to Reduce MT
10-22 UCB: Growth engine isn't out of breath yet Alphavalue
10-22 UCB raises guidance on strength of its two flagship treatments, analysts applaud Zonebourse
10-21 BofA: UCB's Bimzelx Sets 'Very High' Bar Ahead of Q4 Competitor Data in Hidradenitis Suppurativa MT
10-16 FDA green light for UCB and positive view from DB Zonebourse
09-24 BofA Reaffirms UCB at Buy Amid 'Very Confident' Outlook for Psoriasis Drug MT
09-24 BofA Securities Keeps UCB at Buy MT
09-11 AlphaValue/Baader Europe Sees UCB Share Drop as 'Rare Window of Affordability'; Price Target Up MT
09-10 UCB: A rare window of affordability Alphavalue
08-20 Cancer vaccines finally garner the spotlight Alphavalue
08-18 UCB: An unimpressive upgrade-led correction opens a rare opportunity Alphavalue
08-11 Berenberg Adjusts UCB Forecasts After H1 Beat; Buy Reaffirmed MT
08-11 UCB barely moves despite positive calls from ING and Berenberg Zonebourse
07-31 AlphaValue/Baader Europe Upgrades UCB to Add, Trims PT MT
07-30 Kempen Upgrades UCB to Buy Rating, Boosts PT MT
07-14 Where would AI lead Pharma in the long run? Alphavalue
07-03 Berenberg Updates Price Target, Estimates for UCB on Recent Pipeline Deals MT
06-22 UBS Trims UCB's PT, Affirms Buy Rating MT
06-15 UCB Slumps Following Analyst Downgrade Zonebourse
06-15 Barclays Downgrades UCB to Equalweight, Trims PT MT
06-15 UCB Kept at Buy as BofA Notes Psoriasis Drug Momentum MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+7.79%
+3.53%
+3.09%
-0.98%
-2.95%
+13.36%
-1.36%
+23.73%
-12.06%
+0.62%
Average +3.48%
Weighted average by Cap. +3.07%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
270.50EUR
Average target price
291.58EUR
Spread / Average Target
+7.79%
High Price Target
340.00EUR
Spread / Highest target
+25.69%
Low Price Target
208.00EUR
Spread / Lowest Target
-23.11%

Analyst Consensus Detail

Analyst consensus - UCB

Consensus revision (last 18 months)

Consensus revision (last 18 months) - UCB
Trader
Investor
Global
Quality
ESG MSCI
AA
MarketScreener Ratings - UCB